Your browser doesn't support javascript.
loading
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Mizuno, Mika; Ito, Kimihiko; Nakai, Hidekatsu; Kato, Hidenori; Kamiura, Shoji; Ushijima, Kimio; Nagao, Shoji; Takano, Hirokuni; Okadome, Masao; Takekuma, Munetaka; Tokunaga, Hideki; Nagase, Satoru; Aoki, Daisuke; Coleman, Robert L; Nishimura, Yasuko; Ratajczak, Christine K; Hashiba, Hideyuki; Xiong, Hao; Katsumata, Noriyuki; Enomoto, Takayuki; Okamoto, Aikou.
Afiliación
  • Mizuno M; Department of Gynecology, Aichi Cancer Center Hospital, Nagoya-Shi, Aichi, 464-8681, Japan. mizunomizuno@kufm.kagoshima-u.ac.jp.
  • Ito K; Faculty of Medicine, Department of Obstetrics and Gynecology, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima City, 890-8520, Japan. mizunomizuno@kufm.kagoshima-u.ac.jp.
  • Nakai H; Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki-Shi, Hyogo, 660-8511, Japan.
  • Kato H; Department of Obstetrics and Gynecology, Kindai University, Faculty of Medicine, Osakasayama-Shi, Osaka, 589-8511, Japan.
  • Kamiura S; Division of Gynecologic Oncology, Hokkaido Cancer Center, Sapporo-Shi, Hokkaido, 003-0804, Japan.
  • Ushijima K; Department of Gynecology, Osaka International Cancer Institute, Osaka-Shi, Osaka, 541-8567, Japan.
  • Nagao S; Department of Obstetrics and Gynecology, Kurume University Hospital, Kurume-Shi, Fukuoka, 830-0011, Japan.
  • Takano H; Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi-Shi, Hyogo, 673-8558, Japan.
  • Okadome M; Department of Obstetrics and Gynecology, Jikei University Kashiwa Hospital, Kashiwa-Shi, Chiba, 277-0004, Japan.
  • Takekuma M; Gynecology Service, National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, 811-1395, Japan.
  • Tokunaga H; Department of Gynecology, Shizuoka Cancer Center, Sunto-Gun, Shizuoka, 411-8777, Japan.
  • Nagase S; Department of Gynecology, Tohoku University Hospital, Sendai-Shi, Miyagi, 980-8574, Japan.
  • Aoki D; Department of Obstetrics Gynecology, Yamagata University, Faculty of Medicine, Yamagata-Shi, Yamagata, 990-9585, Japan.
  • Coleman RL; Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
  • Nishimura Y; Department of Gynecologic Oncology, US Oncology Research, The Woodlands, TX, USA.
  • Ratajczak CK; AbbVie GK, Minato-Ku, Tokyo, 108-0023, Japan.
  • Hashiba H; AbbVie Inc., North Chicago, IL, USA.
  • Xiong H; AbbVie GK, Minato-Ku, Tokyo, 108-0023, Japan.
  • Katsumata N; AbbVie Inc., North Chicago, IL, USA.
  • Enomoto T; Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki-Shi, Kanagawa, 211-8533, Japan.
  • Okamoto A; Japanese Gynecologic Oncology Group, Shinjuku-Ku, Tokyo, 162-0825, Japan.
Int J Clin Oncol ; 28(1): 163-174, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36534262
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Trombocitopenia / Anemia / Antieméticos Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Trombocitopenia / Anemia / Antieméticos Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón